Molecular docking revealed favorable binding energies between HK2 and quercetin (−8.2 kcal/mol), and between PTAFR and daucosterol (−8.4 kcal/mol), suggesting their potential as effective compounds targeting key genes for COPD therapy. Here, PTAFR is linked to chronic obstructive pulmonary disease.